ECM1

Across TCGA pan-cancer cohorts, ECM1 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ECM1 data layer compared with 23 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in ovarian serous cystadenocarcinoma (OV), where higher ECM1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated ECM1 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

OV, UCEC, and BLCA are the cancer types where ECM1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
OV	DFS	Median	II,III,IV	0.182	0.541	.011	30	view →
UCEC	DFS	Median	All	0.959	0.626	.014	30	view →
BLCA	OS	Median	III,IV	0.190	0.686	<.001	15	view →
COAD	OS	Median	II,III,IV	0.125	0.785	.001	12	view →
LUSC	OS	Median	All	0.043	0.819	<.001	12	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ECM1–OV (DFS)

Open the OV breakdown →